Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

  title={Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies},
  author={V. Jackson and D. Price and P. Carpino},
  journal={Expert Opinion on Investigational Drugs},
  pages={1055 - 1066}
Introduction: The discovery of new antiobesity agents has attracted considerable interest over the past decade, but many of the investigational agents that have advanced into human clinical trials have shown unacceptable adverse events and/or efficacy profiles. Areas covered: This review summarizes the available preclinical and clinical data of antiobesity drugs currently in Phase II clinical trials. It also provides a brief summary of the mechanisms underlying the regulation of energy… Expand
16 Citations

Topics from this paper

Latest approaches for the treatment of obesity
  • 29
Horizons in the Pharmacotherapy of Obesity
  • J. Arch
  • Medicine
  • Current Obesity Reports
  • 2015
  • 11
  • PDF
New perspectives on the development of antiobesity drugs.
  • 4
Obesity: Current and potential pharmacotherapeutics and targets
  • 76
  • Highly Influenced
Neuropeptide receptors as potential pharmacological targets for obesity
  • 6
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
  • Tushar Madaan, M. Akhtar, A. Najmi
  • Chemistry, Medicine
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2016
  • 48


A review of late-stage CNS drug candidates for the treatment of obesity
  • 22
  • PDF
Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
  • 45
Novel strategy for the use of leptin for obesity therapy
  • 36
Current and Future Drug Targets in Weight Management
  • 67
  • PDF
Long-term drug treatment for obesity: a systematic and clinical review.
  • 589
  • PDF
Consensus development conference on antipsychotic drugs and obesity and diabetes.
  • 464
  • PDF
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
  • 136
  • PDF
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
  • 134
Evaluation of efficacy and safety of orlistat in obese patients
  • 23
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
  • J. Shin, K. Gadde
  • Medicine
  • Diabetes, metabolic syndrome and obesity : targets and therapy
  • 2013
  • 35
  • PDF